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Abstract
Background The use of psychotropic medications is not uncommon among patients with newly diagnosed cancer. However, 
the impact of psychotropic polypharmacy on healthcare utilization during the initial phase of cancer care is largely unknown.
Methods We used a claims database to identify adults with incident breast, prostate, lung, and colorectal cancers diagnosed 
during 2011–12. Psychotropic polypharmacy was defined as concurrent use of two or more psychotropic medication classes 
for at least 90 days. A multivariable logistic regression was performed to identify significant predictors of psychotropic 
polypharmacy. Multivariable Poisson and negative binomial regressions were used to assess the associations between psy-
chotropic polypharmacy and healthcare utilization.
Results Among 5604 patients included in the study, 52.6% had breast cancer, 30.6% had prostate cancer, 11.4% had colorec-
tal cancer, and 5.5% had lung cancer. During the year following incident cancer diagnosis, psychotropic polypharmacy was 
reported in 7.4% of patients, with the highest prevalence among patients with lung cancer (14.4%). Compared with patients 
without psychotropic polypharmacy during the initial phase of care, patients with newly diagnosed cancer with psychotropic 
polypharmacy had a 30% higher rate of physician office visits, an 18% higher rate of hospitalization, and a 30% higher rate 
of outpatient visits. The rate of emergency room visits was similar between the two groups.
Conclusion Psychotropic polypharmacy during the initial phase of cancer care was associated with significantly increased 
healthcare resource utilization, and the proportion of patients receiving psychotropic polypharmacy differed by type of cancer.
Impact Findings emphasize the importance of evidence-based psychotropic prescribing and close surveillance of events 
causing increased healthcare utilization among patients with cancer receiving psychotropic polypharmacy.
Key Points 
Prevalence of psychotropic polypharmacy varied by 
type of cancer and approximately 7.4% of patients with 
cancer received psychotropic polypharmacy during the 
first year following cancer diagnosis.
Psychotropic polypharmacy was significantly associated 
with higher rates of physician office visits, outpatient 
visits, and inpatient visits.
1 Introduction
More than 1.5 million new cases of cancer are diagnosed 
each year in USA [1] and mental health and adjustment 
disorders are common among these patients [2, 3]. It is 
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estimated that about 50% of patients diagnosed with can-
cer experience clinically significant psychosocial distress 
and mental health disorders that may have a negative 
impact on their quality of life [2, 4–6]. The Institute of 
Medicine considers psychosocial care an essential part of 
good-quality cancer care and recent treatment guidelines 
have suggested the integration of psychosocial support and 
mental health services into the routine care of patients 
with cancer [7, 8]. Cancer by itself and its treatment 
may precipitate several cancer-related symptoms such as 
fatigue, pain, anorexia, sleep disturbances, and cognitive 
dysfunction [9]. Psychotropic medications are widely used 
to treat these cancer-related symptoms [10]. As a result, 
psychotropic medications have become an important tool 
in a multidisciplinary approach to mental health issues 
related to cancer care [11]. These medications are often 
prescribed for both psychiatric and non-psychiatric cancer 
symptoms [12–18] by psychiatrists, oncologists, and pri-
mary care physicians, especially around the time of diag-
nosis and initial phase of cancer care (i.e., the first year 
following cancer diagnosis) [19–21].
In routine medical practice, psychotropic polypharmacy 
(PP), the concomitant use of two or more classes of psy-
chotropic medications in one patient, is not uncommon 
[22]. Although each drug may have an appropriate indi-
cation, this practice has received much attention in the 
last decade because of increased pill burden, increased 
healthcare cost, and safety concerns related to drug–drug 
interactions not only between psychotropic medications, 
but also between psychotropic medications and anticancer 
medications [23–27]. Accordingly, the annual direct cost 
of cancer care in USA is expected to rise from US$104 
billion in 2006 to about US$173 billion by 2020 with a 
corresponding increase in healthcare resource utilization 
[28, 29]. A few studies have described the use of psycho-
tropic medications in patients with cancer [17–21, 30–32] 
but none have examined the impact of PP on healthcare 
resource utilization during the initial phase of cancer 
care when initial courses of cancer treatment including 
adjuvant therapy are usually expected to be completed. 
This period of active cancer treatment is characterized by 
significant psychosocial distress, psychotropic medica-
tion use, and frequent clinical encounters. Prior studies 
have shown healthcare resource utilization and cancer-
related costs to vary by several factors including cancer 
type, stage at diagnosis, sex, and area of residence [33, 
34] with the greatest expenditure occurring among those 
with metastatic cancer, especially during the last year of 
life [34–36]. The purpose of the study was to examine the 
prevalence of PP, and the relationship between PP and 
healthcare resource utilization during the year following 
the initial diagnosis of breast, prostate, lung, and colorec-
tal cancers.
2  Methods
2.1  Study Design and Data Source
This cross-sectional observational study was conducted 
using an administrative claims database, Optum Clinfor-
matics® Data Mart (OptumInsight, Eden Prairie, MN, 
USA), covering about 22 million enrollees across USA 
from 2010 to 2013. Beneficiaries included in the database 
had both medical and prescription drug coverage. The 
database included demographic and enrollment informa-
tion as well as medical and pharmacy claims. The inpatient 
file captured information on counts of hospitalization and 
lengths of hospital stays. The database is licensed to the 
University of Rhode Island, College of Pharmacy and the 
study protocol was approved by the Institutional Review 
Board of the University of Rhode Island (Kingston, RI, 
USA).
2.2  Study Population
The study was limited to breast, prostate, lung, and colo-
rectal cancers, which represent the most common cancers 
among adults in USA and accounted for 46.3% (US$48 
billion) of the national economic burden of cancer care in 
2006 [29, 37]. We used the following International Clas-
sification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) codes to identify cancer cases diagnosed 
between 1 January, 2011 and 31 December, 2012: 174.xx, 
175.xx, 233.0x for breast, 185.xx, 233.4x for prostate, 
153.xx, 154.xx, 230.3x, 230.4x for colorectal, and 162.xx, 
231.2x for lung cancer [38]. Each patient was required to 
have at least two separate medical claims with the same 
cancer diagnosis having service dates at least 30 days 
apart. The index date was defined as the date of service 
for the initial cancer diagnosis. To allow for adequate 
ascertainment of baseline characteristics and subsequent 
assessment of study outcomes, the analysis was restricted 
to patients with continuous enrollment having both medi-
cal and pharmacy benefits for 12 months before and after 
the index date. The baseline period was defined as the 
12 months preceding the cancer diagnosis and healthcare 
resource utilization was assessed during the initial phase 
of cancer care. We also excluded patients aged younger 
than 18 years, female patients with any claims for prostate 
cancer, male patients with claims for breast cancer, and 
patients with more than one type of cancer or claim for 
metastatic cancer (ICD-9-CM: 196.xx to 198.x) at baseline 
or during the initial phase of cancer care. We excluded 
patients with any known metastatic disease because it is 
not possible to differentiate de novo metastatic cancer 
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from a metastasis occurring following primary incident 
cancer diagnosis using claims data without a chart review. 
The flow chart for the study cohort selection process is 
shown in Table 1.
2.3  Study Measures
2.3.1  Psychotropic Polypharmacy
Psychotropic prescription information was obtained from 
outpatient pharmacy claims and categorized using the Amer-
ican Hospital Formulary Service Pharmacologic Therapeu-
tic Classification System therapeutic class codes. Psycho-
tropic medication were categorized by drug class according 
to their standard use as antidepressants, antipsychotics, 
anticonvulsants, anxiolytics-sedatives-hypnotics (including 
barbiturates), and central nervous system stimulants/psycho-
stimulants. These classes of psychotropic medications were 
selected based on published reviews about the use of psy-
chotropic medications among patients with cancer [39, 40]. 
Psychotropic medication use was defined as the receipt of at 
least one prescription in the psychotropic medication classes 
during the study period. Psychotropic polypharmacy was 
defined as the concurrent use of two or more psychotropic 
medication classes for at least 90 days [25, 41, 42].
2.3.2  Healthcare Resource Utilization
Healthcare Common Procedure Coding System procedure 
codes, place of service, and revenue codes were used to iden-
tify specific types of healthcare resource utilization includ-
ing office visits, outpatient visits, and emergency room (ER) 
visits during the initial phase of care. We used the inpatient 
data file to identify inpatient admissions and length of inpa-
tient stay during the initial phase of care. Multiple claims 
with the same procedure code, place of service, and claim 
date were considered duplicates and only one claim was con-
sidered for assessing healthcare utilization. Each claim was 
treated as a distinct medical encounter, visit, or event. Office 
visits included claims for services performed in a physician’s 
office while outpatient visits included encounters outside a 
doctor’s office for which a patient is able to return home after 
care without an overnight stay including visits to hospital 
outpatient departments, oncology clinics, ambulatory care 
surgical centers, outpatient rehabilitation facilities, rural 
health clinics, and community mental health centers. Office 
visits were identified with procedure codes 99201–99205 
and 99211–99215; outpatient visits with procedure codes 
99241–9245, 99341–99350, 99381–99387, 99391–99397, 
99401–99404, 99411, 99412, 99420, 99429, 99455, and 
99456; and ER visits with procedure codes 99281–99288.
2.3.3  Covariates
Demographic characteristics obtained from the member-
ship file included age at initial cancer diagnosis, sex, type 
of health plan (point of service, exclusive provider organi-
zation, health maintenance organization, and others), and 
US geographic census region (Northeast, South, Midwest, 
and West). Clinical characteristics consisted of the type of 
cancer (breast, prostate, lung, colorectal), Charlson comor-
bidity indices, psychiatric comorbidities, and chemotherapy 
and radiation therapy; the latter were captured with ICD-
9-CM codes V58.11 and V58.0, respectively. Charlson 
comorbidity indices were calculated for each patient based 
on the presence of claims for certain diagnosis during the 
year prior to cancer diagnosis [43]. In addition to dementia 
being included in the Charlson comorbidity measure, we 
also controlled additional baseline psychiatric conditions 
such as depression, anxiety, dysthymia, post-traumatic stress 
disorder, bipolar disorder, personality disorder, schizophre-
nia, and other psychotic disorders [32, 44, 45]. These were 
obtained from the medical file using their respective ICD-
9-CM codes.
2.4  Statistical Analysis
Descriptive statistics were computed for baseline demo-
graphic and clinical characteristics and differences between 
patients with and without PP during the initial phase of care 
were compared using Chi-square goodness-of-fit tests (for 
categorical variables) and t tests (for continuous variables). 
The prevalence of PP overall and by type of cancer were 
also estimated and compared using t tests. The mean number 
of prescriptions for psychotropic medications prescribed to 
patients and the prevalence of PP during the baseline period 
Table 1  Study cohort selection N Criteria met
26,064 Claims for one type of cancer between 1/1/2011 and 31/12/2012
15,292 Continuous enrolled for 1 year before and after cancer diagnosis
15,279 After excluding male with female individuals with cancers and vice versa
14,733 After excluding patients with metastatic cancer during initial phase of care
14,176 After excluding patients aged younger than 18 years
5604 Patients with breast, prostate, lung, and colorectal cancers only
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and initial phase of care overall and by type of cancer were 
estimated using t tests. To identify potential predictors of 
PP among patients with cancer, first, a multivariable logistic 
regression model was conducted.
The frequency and rates of office visits, outpatient vis-
its, ER visits, inpatient admissions, and length of inpatient 
stay during the initial phase of cancer care were determined. 
The unadjusted cumulative incidence rate for each type of 
healthcare resource utilization was computed as the sum of 
all events or the total number of patients who experienced 
the incident event of interest per cohort divided by the total 
person-time at risk for the entire cohort [46]. Second, mul-
tivariable regressions were performed to evaluate if PP vs. 
no PP was associated with each component of healthcare 
resource utilization. Adjusted incidence rate ratios (aIRRs) 
were estimated using either a Poisson (number of admis-
sions) or a negative binomial (number of outpatient visits, 
office visits, ER visits, and hospital length of stay) regres-
sion based on a model fit for our data, after controlling for all 
the covariates (Appendix 1 of the Electronic Supplementary 
Material [ESM]). A goodness-of-fit Chi-square test was used 
to assess the fit of each model assuming that the deviance 
follows a Chi-square distribution with degrees of freedom 
equal to the model residual [47] (eTable 3 of the ESM).
All statistical analyses were two sided and conducted at 
the 0.05 significance level. Statistical analyses were per-
formed using the Statistical Analysis Systems software 
 (SAS® Version 9.4, SAS Institute Inc., Cary, NC, USA).
3  Results
3.1  Study Population and Baseline Characteristics
A total of 5604 patients with newly-diagnosed cancer were 
included in the study, of which 52.6% had breast cancer, 
30.6% had prostate cancer, 11.4% had colorectal cancer, and 
5.5% had lung cancer. Four hundred and sixteen patients 
(7.4%) received PP during the initial phase of cancer care 
(Table 2). Overall, more than 77% of patients were between 
the ages of 45 and 64 years, 61% were female, 74.6% had 
a point of service health plan, and 68% received medical 
care in the Southern US census region. A majority of these 
patients had a Charlson comorbidity score of 0 (66.5%) 
or did not have any diagnoses for psychiatric conditions 
(93.8%) at baseline. The distributions of clinical and demo-
graphic characteristics among patients who received PP dur-
ing the year following cancer diagnosis were significantly 
different from those without PP, except for type of health 
plan. At baseline, a majority of patients prescribed PP were 
more likely to be female (81.3%) aged 55–64 years (56.5%) 
with breast cancer (65.1%) as compared to those without 
PP. Furthermore, patients who received PP during the initial 
phase of care were more likely to have a Charlson comor-
bidity index of at least 1 and mental illness before cancer 
diagnosis compared with patients who did not receive PP. A 
total of 39,001 psychotropic medication prescriptions were 
filled during the 2-year period around initial cancer diag-
noses, of which 20,970 (53.8%) were prescribed during the 
initial phase of care, 18,336 (47%) were antidepressants, 
and 13,252 (34%) were anxiolytics (eTable 1 of the ESM).
3.2  Prevalence and Predictors of Psychotropic 
Polypharmacy
The proportion of patients who received PP during the 
1 year prior to cancer diagnosis increased among all types 
of cancers during the initial phase of cancer care (Table 3). 
On average, the proportion of patients on PP increased sig-
nificantly from 6.2% before to 7.4% after cancer diagnosis. 
More than 90% of patients who received PP during the initial 
phase of care had an antidepressant as a component of their 
PP combination (eTable 2 of the ESM). Use of PP during 
the initial phase of care differed by cancer type, with patients 
with lung cancer (14.4%) more likely to have PP compared 
with patients with breast (9.2%), prostate (2.9%), or colorec-
tal (8.0%) cancers. There was a corresponding increase in 
the average number of psychotropic drug prescriptions dur-
ing the 12 months preceding the index date compared with 
the 12 months following the initial cancer diagnosis for all 
types of cancers, except for a relatively small but statistically 
non-significant decrease among patients with lung cancer 
(Table 4). For instance, the mean number of psychotropic 
drug prescriptions among patients with colorectal cancer 
increased from 7.95 (standard deviation = 8.97) at baseline 
to 8.91 (standard deviation = 8.90) during the initial phase 
of care.
Sex, age group at cancer diagnosis, presence of psychi-
atric conditions, and physical comorbidity at baseline were 
significant predictors of the use of PP during the initial 
phase of cancer care (Table 5). After controlling for other 
variables in the model, patients aged 55–64 years were more 
likely to receive PP compared with those aged 18–44 years 
(adjusted odds ratio [aOR] = 1.69; 95% confidence inter-
val [CI] 1.07–2.65); female patients were two times more 
likely to receive PP than male patients (aOR = 2.15; 95% CI 
1.32–3.49); and patients with cancer residing in the South 
were 1.5 times more likely to use PP than those residing in 
the Northeast (aOR = 1.51; 95% CI 1.09–2.08). In addition, 
patients with cancer with one or more psychiatric diagnostic 
conditions (aOR = 8.39; 95% CI 6.32–11.19 for one con-
dition; aOR = 11.19; 95% CI 6.42–19.52 for two or more 
conditions) were more likely to receive PP compared with 
those without any psychiatric condition at baseline. Finally, 
patients with cancer with at least one comorbidity score 
(aOR = 1.70; 95% CI 1.32–2.18 for one score; aOR = 2.21; 
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95% CI 1.61–3.04 for two or more scores) were more likely 
to have PP compared with those without any physical comor-
bidity at baseline.
3.3  Rates of Healthcare Resource Utilization
Nearly 45% of all patients had at least one outpatient and 
office visit, 18.5% required at least one hospital admission, 
and 15.7% had at least one ER visit during the initial phase 
of cancer care. Table 6 presents a summary of the unadjusted 
and adjusted rates of healthcare resource utilization among 
patients with cancer with and without PP during the initial 
phase of cancer care. After adjusting for age at cancer diag-
nosis, sex, type of health plan, geographic region, cancer 
Table 2  Baseline characteristics 
of patients diagnosed with 
breast, prostate, lung, and 
colorectal cancers in USA 
(n = 5604)
EPO exclusive provider organization, HMO health maintenance organization, POS point of service, PP 
psychotropic polypharmacy




n = 5188 (92.6%)
PP
n = 416 (7.4%)
P value
Age group at index (years)
 18–44 408 (7.28) 382 (7.36) 26 (6.25) 0.0202
 45–54 1505 (26.86) 1396 (26.91) 109 (26.20)
 54–64 2822 (50.36) 2587 (49.87) 235 (56.49)
 65+ 869 (15.51) 823 (15.86) 46 (11.06)
Sex
 Female 3418 (60.99) 3080 (59.37) 338 (81.25) <0.0001
 Male 2186 (39.01) 2108 (40.63) 78 (18.75)
Type of health plan
 EPO 727 (12.97) 679 (13.09) 48 (11.54) 0.0748
 HMO 295 (5.26) 277 (5.34) 18 (4.33)
 Othersa 401 (7.16) 359 (6.92) 42 (10.10)
 POS 4181 (74.61) 3873 (74.65) 308 (74.04)
Geographic region
 Midwest 1582 (28.23) 1466 (28.26) 116 (27.88) 0.0500
 Northeast 1042 (18.60) 978 (18.85) 64 (15.38)
 South 2265 (40.40) 2073 (39.97) 192 (46.15)
 West 714 (12.74) 670 (12.92) 44 (10.58)
Type of cancer
 Breast 2946 (52.57) 2675 (51.56) 271 (65.14) < 0.0001
 Colorectal 636 (11.35) 585 (11.28) 51 (12.26)
 Lung 306 (5.46) 262 (5.05) 44 (10.58)
 Prostate 1716 (30.62) 1666 (32.11) 50 (12.02)
No. of psychiatric conditions
 None 5256 (93.79) 4967 (65.74) 289 (69.47) < 0.0001
 1 288 (5.14) 189 (3.64) 99 (23.80)
 2+ 60 (1.07) 32 (0.62) 28 (6.73)
Charlson Comorbidity Index
 0 3729 (66.54) 3513 (67.71) 216 (51.92) < 0.0001
 1 1252 (22.34) 1129 (21.76) 123 (29.57)
 2+ 623 (11.12) 546 (10.52) 77 (18.57)
Table 3  Distribution of psychotropic polypharmacy among adults 
with common cancer types in USA
The proportion of patients with psychotropic polpharmacy at baseline 
and during the initial phase of care differed significantly for all cancer 
types (Chi square test: p < 0.0001)
Cancer types Total population, n 
(%)
Baseline, n (%) Initial phase 
of care, n (%)
Breast 2946 (52.57) 229 (7.77) 271 (9.20)
Colorectal 636 (11.35) 42 (6.60) 51 (8.02)
Lung 306 (5.46) 30 (9.80) 44 (14.38)
Prostate 1716 (30.62) 44 (2.56) 50 (2.91)
Overall 5604 345 (6.16) 416 (7.42)
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type, number of psychiatric conditions and Charlson comor-
bidity index at baseline, and use of radiation and chemo-
therapy during the initial phase of cancer care, patients who 
received PP had about a 30% higher rate of both outpatient 
and physician office visits (aIRR = 1.28; 95% CI 1.21–1.36 
and aIRR = 1.30; 95% CI 1.23–1.38, respectively), 18% 
higher rates of hospital admissions (aIRR = 1.18; 95% CI 
1.07–1.31), and a 30% increase in the length of hospital 
inpatient stays (aIRR = 1.30; 95% CI 1.11–1.52), than those 
without PP. The rates of ER visits were 4% higher among 
patients who received PP than those who did not receive PP 
but this difference was not statistically significant. A more 
detailed result of the adjusted models estimated using the 
Poisson and negative binomial regressions is provided in 
eTable 3 of the ESM.
4  Discussion
Several cancer- or cancer treatment-related symptoms are 
managed with psychotropic medications [9, 10, 19–21, 48]. 
In certain clinical situations, the use of more than one psy-
chotropic medication is appropriate and supported by empir-
ical evidence. For example, the addition of antipsychotics to 
either antidepressants for the treatment of major depression 
with psychotic features [49] or to mood stabilizers for the 
management of acute mania [50] is considered the standard 
of care. Similarly, the short-term use of benzodiazepines 
with antidepressants to treat major depression may be clini-
cally justified [51]. Furthermore, patients with treatment-
resistant disease may require dual therapy, and for many 
patients, depression, anxiety, pain, and psychosis may coex-
ist, warranting the use of multiple psychoactive medications.
We examined the prevalence of PP, predictors of the 
use of PP during the initial phase of cancer care, and the 
association between the use of PP and healthcare resource 
utilization. We found that the proportion of patients who 
received PP increased slightly from the baseline period to 
the initial phase of cancer care among all patients and for 
all cancer types included in our study. Prevalence of psy-
chotropic medication use and PP at baseline were relatively 
low (6.2%), likely because most patients in our cohort did 
not have any psychiatric conditions during the year leading 
up to their first cancer diagnosis. A previous study found 
that the risk of mental health disorders is temporally related 
to the diagnostic work-up for suspected cancer with a cor-
responding increased use of psychotropic medications from 
about a month before a cancer diagnosis that peaks at about 
3 months after [52]. This may explain the modest overall 
increase in the prevalence of PP use from 6.2% at baseline 
to 7.4% after cancer diagnosis in our study sample.
In this study, we found that in addition to the number of 
psychiatric conditions at baseline, sex, age at cancer diag-
nosis, and physical comorbidity at baseline were also sig-
nificant predictors of the use of PP during the initial phase 
of cancer diagnosis. Type of cancer was not a significant 
predictor of PP use during the initial phase of cancer care. 
This finding is partially similar to that reported in a previous 
study that showed no significant association between type 
of cancer and the use of antidepressants [53]. Other studies 
have found a similarly higher prevalence of psychotropic 
medication use and PP among women and patients with 
comorbid conditions [21, 30, 54].
A higher prevalence of PP was observed among patients 
with lung, colorectal, and breast cancers compared with 
those with prostate cancer. These findings are consistent 
with those reported in an analysis of self-reported medica-
tion use among survivors of patients with breast, lung, and 
colorectal cancers [30]. A retrospective cohort study of com-
munity-based Medicare beneficiaries also found that patients 
with prostate cancer were least likely to receive any psycho-
tropic medications compared with patients with breast, lung, 
and colorectal cancers [55]. One potential reason for a lower 
prevalence of PP among patients with prostate cancer is that 
a diagnosis of prostate cancer may be associated with less 
psychosocial distress requiring pharmacotherapy because a 
Table 4  Average number of 
prescriptions of psychotropic 
medications among  adultsa with 
common cancer types in USA
CI confidence interval
The mean number of psychotropic medications used at baseline and during the initial phase of cancer care 
did not differ significantly both overall and for each type of cancer (t test: p > 0.05)
a Among those with at least one psychotropic medication prescription during baseline or during the initial 
phase of care
Cancer types At baseline During the initial phase of care
N (%) Mean (95% CI) N (%) Mean (95% CI)
Breast 1388 (62.21) 8.45 (7.98–8.92) 1518 (63.28) 9.00 (8.53–9.47)
Colorectal 231 (10.35) 7.95 (6.79–9.11) 262 (10.92) 8.91 (7.83–10.00)
Lung 159 (7.13) 10.14 (8.49–11.78) 181 (7.54) 10.03 (8.50–11.55)
Prostate 453 (20.30) 6.30 (5.63–6.96) 438 (18.26) 7.22 (6.53–7.92)
Overall 2231 (100) 8.08 (7.72–8.45) 2399 (100) 8.74 (8.38–9.11)
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significant portion of patients with prostate cancer die with 
the disease rather than from the disease.
We found that the use of PP during the first year after 
a cancer diagnosis was associated with increased rates of 
outpatient visits, office visits, inpatient admissions, and 
length of hospital stay after adjusting for certain poten-
tial confounding factors. Patients with newly diagnosed 
cancer often require chemotherapy and concurrent use of 
multiple psychotropic medications places them at a sig-
nificantly higher risk of adverse drug–drug interactions 
that may require additional healthcare services for their 
effective management [24, 27, 56]. Patients who received 
PP in our study were more likely to have many chronic 
physical and psychiatric conditions. This may explain why 
they experienced more frequent clinical encounters and 
received more psychotropic medications. To the best of 
Table 5  Factors associated 
with use of psychotropic 
polypharmacy among adults 
with common cancer types 
during the year following cancer 
diagnosis in USA
Bold values indicate p < 0.05
CI confidence interval, EPO exclusive provider organization, HMO health maintenance organization, OR 
odds ratio, POS point of service
a Others include indemnity and preferred provider organizations
Variables Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age group at index (years)
 18–44 Ref. Ref
 45–54 1.15 (0.74–1.79) 1.25 (0.78–2.00)
 54–64 1.34 (0.88–2.03) 1.69 (1.07–2.65)
 65+ 0.82 (0.50–1.35) 1.13 (0.65–1.97)
Sex
 Male Ref. Ref
 Female 2.97 (2.30–3.82) 2.15 (1.32–3.49)
Type of health plan
 HMO Ref. Ref.
 EPO 1.09 (0.62–1.90) 1.03 (0.57–1.87)
 Othersa 1.80 (1.01–3.20) 1.82 (0.98–3.39)
 POS 1.22 (0.75–2.00) 1.27 (0.76–2.14)
Geographic region
 Northeast Ref. Ref.
 Midwest 1.21 (0.88–1.66) 1.26 (0.89–1.77)
 South 1.42 (1.06–1.90) 1.51 (1.09–2.08)
 West 1.00 (0.678–1.49) 1.13 (0.74–1.73)
Type of cancer
 Breast Ref. Ref.
 Colorectal 0.86 (0.630–1.18) 1.29 (0.89–1.88)
 Lung 1.66 (1.176–2.34) 1.46 (0.96–2.22)
 Prostate 0.30 (0.218–0.40) 0.62 (0.35–1.12)
Chemotherapy
 No Ref. Ref.
 Yes 1.46 (1.07–1.98) 1.15 (0.81–1.64)
Radiotherapy
 No Ref. Ref.
 Yes 1.00 (0.673–1.47) 0.86 (0.55–1.33)
No. of psychiatric conditions
 None Ref. Ref.
 1 9.00 (6.87–11.80) 8.39 (6.32–11.13)
 2+ 15.04 (8.93–25.32) 11.19 (6.42–19.52)
Charlson Comorbidity Index
 0 Ref. Ref.
 1 1.77 (1.41–2.23) 1.70 (1.32–2.18)
 2+ 2.29 (1.74–3.02) 2.21 (1.61–3.04)
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the authors’ knowledge, this is the first study to examine 
the prevalence and predictors of PP during the first year of 
cancer care among patients with newly diagnosed breast, 
prostate, lung, and colorectal cancers in USA using a large 
insured adult population.
Our study design has some limitations. First, multiclass 
PP relies on a grouping of psychotropic medications into 
classes that is based on certain clinical syndromes or mecha-
nisms of action that may not fully capture their pharma-
cological properties. In recent years, some psychotropic 
medications have received approvals for multiple indica-
tions. Because we did not assess the appropriateness of PP 
or adverse effects, we do not know if increased healthcare 
utilization is directly attributable to the consequences of PP 
or mental healthcare. In addition, some information that may 
impact on the use of psychotropic medications on health-
care resource utilization was not captured in our data source. 
Specifically, data on variables such as race/ethnicity, socio-
economic status, clinical information about the cancer (e.g., 
severity, tumor stage, tumor size, and tumor grade), perfor-
mance status, and patient preferences and beliefs about alter-
native treatments was not available in the extant database. 
Second, a cross-sectional design limits our ability to make 
causal inferences owing, in part, to lack of temporality. We 
also conditioned our analysis on survival during the initial 
phase of care and occurrence of metastatic disease measured 
after baseline, which could induce selection bias. As a result, 
the true rates of PP among patients with cancer are likely 
higher than our estimates because psychotropic medication 
use often starts during evaluations for suspected cancer and 
peaks after cancer diagnosis, and may persist during ter-
minal care [21]. Patients who had more advanced cancers 
and died during the initial phase of care were excluded, 
which may have resulted in healthier patients included in 
our analysis, as compared to all patients with incident cancer 
in the database. The list of procedure codes for office visits 
may not be exhaustive. Last, the study focused only on a 
commercially insured population, hence the findings may 
not be generalizable to other populations.
5  Conclusion
Patients with PP during the initial phase of cancer care uti-
lized more healthcare resources than those without PP. There 
was a small but statistically significant increase in the use of 
psychotropic medications and PP after initial cancer diag-
nosis, and the proportion of patients receiving PP differed 
by the type of cancer. Given current treatment guideline rec-
ommendations, this increase may be the result of a greater 
inclusion of a psychiatrist specialized in psycho-oncology 
in multidisciplinary cancer care teams, and the availability 
of newer psychotropic medications. Psychotropic medica-
tion use may be an indicator of better assessments of psy-
chosocial distress associated with a new cancer diagnosis. 
These findings emphasize the importance of evidence-based 
psychotropic prescribing and close surveillance for potential 
adverse psychotropic drug–drug interactions in patients with 
cancer, and suggest that patients with cancer with mental 
health illnesses, even when treated, require a higher degree 
of healthcare services. Further research is needed to deter-
mine the proportion of increased healthcare resource utiliza-
tion in this population attributable to the underlying mental 
health co-morbidity, or psychotropic medication side effects, 
interactions, or other potential adverse outcomes of therapy.
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Table 6  Unadjusted and adjusted rates of healthcare resource utiliza-
tion during the initial phase of cancer care comparing patients with 
psychotropic polypharmacy (PP) and without PP among adults with 
common cancer types in USA
Bold values indicate p < 0.05
CI confidence interval, ER emergency room, IRR incidence rate ratio
a Adjusted for age at index, sex, type of health plan, geographic 
region, cancer type, psychiatric conditions, and Charlson Comorbid-
ity Index at baseline, and use of radiation and chemotherapy during 
the initial phase of cancer care
Healthcare resource 
utilized
Unadjusted IRR Adjusted IRR (95% CI)a
Number of outpatient 
visits
1.25 (1.21–1.28) 1.28 (1.21–1.36)
Number of office visits 1.26 (1.23–1.29) 1.30 (1.23–1.38)
Number of ER visits 1.19 (1.09–1.29) 1.04 (0.88–1.23)
Number of admissions 1.27 (1.16–1.40) 1.18 (1.07–1.31)
Length of stay (days) 1.34 (1.25–1.43) 1.30 (1.11–1.52)
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provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
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